ICON Expands Asia Pacific Footprint With New Focus On Southeast Asian Countries
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Driven by increasing interest for drug development programs in Southeast Asia, Ireland-based ICON is expanding its Asia Pacific footprint in the Philippines
You may also be interested in...
Boehringer sees advantages to a long-term, and expansive CRO partnership instead of carving up markets in Asia.
Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.